Skip to main content
PMC home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2003 Sep 21;341(8844):515–518. doi: 10.1016/0140-6736(93)90277-N

High serum procalcitonin concentrations in patients with sepsis and infection

M Assicot a, C Bohuon a,*, D Gendrel b, J Raymond c, H Carsin d, J Guilbaud d
PMCID: PMC7141580  PMID: 8094770

Abstract

High concentrations of calcitonin-like immunoreactivity have been found in the blood of patients with various extrathyroid diseases. By means of a monoclonal immunoradiometric assay for calcitonin precursors, we have measured serum concentrations of procalcitonin in patients with various bacterial and viral infections. 79 children (newborn to age 12 years) in hospital with suspected infections were investigated prospectively. 19 patients with severe bacterial infections had very high serum concentrations of procalcitonin at diagnosis (range 6-53 ng/mL) in comparison with 21 children found to have no signs of infection (baseline concentrations <0·1 ng/mL). Serum procalcitonin values decreased rapidly during antibiotic therapy. 11 patients with peripheral bacterial colonisation or local infections without invasive sepsis and 18 (86%) of 21 patients with viral infections had concentrations within or slightly above the normal range (0·1-1·5 ng/mL). Among 9 severely burned patients studied in an intensive care unit, the post-traumatic course of procalcitonin concentrations (range 0·1-120 ng/mL) was closely related to infectious complications and acute septic episodes. Concentrations of mature calcitonin were normal in all subjects, whatever procalcitonin concentrations were found. Concentrations of a substance immunologically identical to procalcitonin are raised during septic conditions. Serum concentrations seem to be correlated with the severity of microbial invasion.

References

REFERENCES

  • 1.Coombes Rc, Hillyard C., Greenberg Pb, MacIntyre I. Plasma immunoreactive-calcitonin in patients with non-thyroid tumours. Lancet. 1974;1:1080–1083. doi: 10.1016/s0140-6736(74)90557-1. [DOI] [PubMed] [Google Scholar]
  • 2.Milhaud G., Calmette C., Taboulet Jj, Julienne A., Moukhtar M. Hypersecretion of calcitonin in neoplastic conditions. Lancet. 1974;i:462–463. doi: 10.1016/s0140-6736(74)92428-3. [DOI] [PubMed] [Google Scholar]
  • 3.Becker Kl, Nash Dr, Silva Ol. Increased serum and urinary calcitonin levels in patients with pulmonary disease. Chest. 1981;79:211–216. doi: 10.1378/chest.79.2.211. [DOI] [PubMed] [Google Scholar]
  • 4.Canale Dd, Donabedian Rk. Hypercalcitoninemia in acute pancreatitis. J Clin Endocrinol Metab. 1975;40:738–740. doi: 10.1210/jcem-40-4-738. [DOI] [PubMed] [Google Scholar]
  • 5.Gillquist J., Larsson J., Sjodahl R. Serum calcitonin in acute pancreatitis in man. Scand J Gastroenterol. 1977;12:21–23. [PubMed] [Google Scholar]
  • 6.Silva O., Becker Kl, Shalhoub Rj, Snider Rh, Bivins Le, Moore Cf. Calcitonin levels in chronic renal disease. Nephron. 1977;19:12–18. doi: 10.1159/000180860. [DOI] [PubMed] [Google Scholar]
  • 7.Fauchald P., Gautvik Vt, Gautvik Km. Immunoreactive parathyroid-hormone and calcitonin in plasma and ultrafiltrate before and after haemodialysis. Scand J Clin Lab Invest. 1985;45:229–235. doi: 10.3109/00365518509161000. [DOI] [PubMed] [Google Scholar]
  • 8.Ghillani P., Motte P., Troalen F. Identification and measurement of calcitonin precursors in serum of patients with malignant diseases. Cancer Res. 1989;49:6845–6851. [PubMed] [Google Scholar]
  • 9.Mallet E., Lanse X., Devaux Am. Hypercalcitoninaemia in fulminant meningococcaemia in children. Lancet. 1983;1:294. doi: 10.1016/s0140-6736(83)91704-x. [DOI] [PubMed] [Google Scholar]
  • 10.Heath H., Sizemore Gw, Larson Jm, Jerpback Cm. Immunochemical heterogeneity of calcitonin in tumor, tumor venous effluent and peripheral blood of patients with medullary thyroid carcinoma. J Lab Clin Med. 1979;93:390–394. [PubMed] [Google Scholar]
  • 11.Deftos Lj, Ross Ba, Bronzert D., Pathermore Jg. Immunochemical heterogeneity of calcitonin in plasma. J Clin Endocrinol Metab. 1975;40:409–412. doi: 10.1210/jcem-40-3-409. [DOI] [PubMed] [Google Scholar]
  • 12.Roos Ba, Huber Mb, Brinbaum Bs. Medullary thyroid carcinoma secretes a non-calcitonin peptide corresponding to the carboxyl terminal region of preprocalcitonin. J Clin Endocrinol Metab. 1983;56:802–807. doi: 10.1210/jcem-56-4-802. [DOI] [PubMed] [Google Scholar]
  • 13.Born W., Beglinger C., Fischer Ja. Diagnostic relevance of the amino-terminal cleavage peptide of procalcitonin (PAS-57), calcitonin and calcitonin gene-related peptide in medullary thyroid carcinoma patients. Regul Pep. 1991;32:311–319. doi: 10.1016/0167-0115(91)90024-b. [DOI] [PubMed] [Google Scholar]
  • 14.Colon Jm, Grimelius L., Thim L. Structural characterization of a high-molecular-mass form of calcitonin [procalcitonin-(60-116) -peptide] and its corresponding N-terminal flanking peptide [procalcitonin-(1-57)-peptide] in a human medullary thyroid carcinoma. Biochemistry. 1988;256:245–250. doi: 10.1042/bj2560245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Becker Kl, Monaghan Kg, Silva Ol. Immunocytochemical localization of calcitonin in Kultschitzky cells of human lung. Arch Pathol Lab Med. 1980;104:196–198. [PubMed] [Google Scholar]
  • 16.Minvielle S., Giscard-Dartevelle S., Cohen R. A novel calcitonin carboxy-terminal peptide produced in medullary thyroid carcinoma by alternative RNA processing of the calcitonin/calcitonin gene-related peptide gene. J Biol Chem. 1991;36:24627–24631. [PubMed] [Google Scholar]
  • 17.Joyce Cd, Fiscus Rr, Wang X. Calcitonin gene-related peptide levels are elevated in patients with sepsis. Surgery. 1990;108:1097–1101. [PubMed] [Google Scholar]

Articles from Lancet (London, England) are provided here courtesy of Elsevier

RESOURCES